Analyzing Crescent Biopharma (NASDAQ:CBIO) & C4 Therapeutics (NASDAQ:CCCC)

Crescent Biopharma (NASDAQ:CBIO) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Institutional & Insider Ownership

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Crescent Biopharma and C4 Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Risk & Volatility

Crescent Biopharma has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500.

Valuation & Earnings

This table compares Crescent Biopharma and C4 Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84 million	57.87	-$153.94 million	($6.72)	-2.51
C4 Therapeutics	$35.95 million	11.60	-$104.99 million	($1.00)	-3.39

C4 Therapeutics has higher revenue and earnings than Crescent Biopharma. C4 Therapeutics is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Crescent Biopharma and C4 Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1	1	2	2	2.83
C4 Therapeutics	1	0	4	0	2.60

Crescent Biopharma currently has a consensus price target of $29.60, indicating a potential upside of 75.25%. C4 Therapeutics has a consensus price target of $7.67, indicating a potential upside of 126.16%. Given C4 Therapeutics’ higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Crescent Biopharma.

Summary

C4 Therapeutics beats Crescent Biopharma on 9 of the 15 factors compared between the two stocks.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.